Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Branded Advair Breathes Another Day; Mylan Says A CRL Is On The Way For A Generic

Executive Summary

FDA alerted Mylan to expect a complete response letter related to its ANDA for generic Advair. The company said it still could receive an approval prior to the standard 90-day time period after responding to the letter, because the application has a priority designation.

Advertisement

Related Content

Pharma Q3 Preview: Amgen, Allergan, Pfizer, GSK And Sanofi
Mylan To Explore Strategic Options, Claiming Investors Have Failed To Appreciate The Value
GSK's Big Reveal: An R&D Overhaul Poised To Yield Long-Term Cultural Change
Mylan Is First To Clear US Neulasta Biosimilar Hurdle; At-Risk Launch May Not Be Risky
Mylan Poised To Launch Its First US Biosimilar, With A Stacked Pipeline Behind It
Three Strikes For Generic Advair With An FDA CRL For Sandoz
Walmsley: GSK Is 'Prepared' And 'Ready' For US Advair Generic Launch
Mylan’s Generic Advair Delay Gives Leverage To Rivals

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123254

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel